QEL-005 / Quell Therap - LARVOL DELTA

Quell Therapeutics to Unveil Promising Data for QEL-005, a Novel CAR-Treg Cell Therapy for Complex Autoimmune Diseases, at ACR Convergence 2025 (GlobeNewswire) - "Results from pre-clinical studies demonstrate immunomodulatory activity of QEL-005 across multiple immune cell lineages involved in complex autoimmune inflammation, including B cells, T cells and inflammatory macrophages....Data being presented supports CTA filings in Q4 ahead of initiating the CHILL clinical study in H1 2026 in patients with Rheumatoid Arthritis and Systemic Sclerosis."

New trial • Preclinical • Rheumatoid Arthritis • Systemic Sclerosis

QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis (ACR Convergence 2025) - "In diseases such as RA and SSc with complex interactions of immune effector and tissue cell types, QEL-005 CD19 CAR-Tregs have the potential to durably restore homeostasis in chronically inflamed tissues with limited risk of drug associated toxicity."

IO biomarker • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Sclerosis • CD80 • FOXP3